GSK (NYSE:GSK) is pursuing a focused oncology expansion built around hematologic malignancies, gynecologic cancers, lung ...

GSK plc GSK has entered into an agreement to acquire an investigational trispecific T-cell engager (TCE) from Chimagen ...

GSK has delivered a solid multi year share price run, helped by fresh moves in oncology and vaccines, and that raises a ...

GSK is acquiring global rights to a T cell engager that Chimagen Biosciences developed to hit three targets. GSK believes this tri-specific approach could offer advantages over currently available ...

GSK said Chief Executive Emma Walmsley would step down and be succeeded by commercial chief Luke Miels, as the drugmaker works to replenish its product lineup. Walmsley will step down at the end of ...

(Alliance News) - GSK PLC on Tuesday said it has agreed to buy "a potential best-in-class" T cell-engager aimed at treating multiple myeloma from China-based clinical-stage biotechnology company ...

According to Sharecast on September 18, 2026, Berenberg upgraded GSK from Hold to Buy and lifted its target price on the stock from GBP 20 to GBP 22, arguing that recent business-development ...

GSK said its Jideytro drug showed benefits for patients with a type of lung cancer in a clinical trial, a finding that could help the company seek approval for the medicine at an earlier stage of ...

For GSK CEO Emma Walmsley, there was good news and bad news in the company’s annual report. While it revealed (PDF) that Walmsley took a 16% pay cut in 2024, it also laid out a new compensation plan ...

Biopharma company GSK reached settlement agreements with 10 law firms representing multiple plaintiffs in cases related to the company allegedly selling carcinogenic drugs. The settlement affects ...

GSK PLC GSK +1.87% shares rose 4.74% to £18.55 Monday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX -0.28% rising 0.44% to 10,697.57.

Sept 15 (Reuters) - GSK said on Tuesday it had agreed a deal worth up to $750 million to buy a trispecific T cell-engager (TCE), a drug designed to help T-cells target cancer, from China-based ...